Last reviewed · How we verify
meglitinides
At a glance
| Generic name | meglitinides |
|---|---|
| Also known as | oral hypoglycemic agent, repaglinide, nateglinide |
| Sponsor | Sanofi |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease (PHASE2)
- Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes
- Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial (PHASE4)
- Dapagliflozin Effect in Cognitive Impairment in Stroke Trial (PHASE2, PHASE3)
- Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes (PHASE4)
- A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment (PHASE3)
- A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey (PHASE4)
- Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- meglitinides CI brief — competitive landscape report
- meglitinides updates RSS · CI watch RSS
- Sanofi portfolio CI